Skip menus, go to main page content

To Our Shareholders
and Investors

Top
To Our Shareholders and Investors

IR News

December 23, 2025

R & D

Nippon-Shinyaku and FRONTEO Launch Co-Creation Project to Evaluate Drug Discovery Seeds
December 22, 2025

R & D

ELZONRIS® I.V. Injection Receives Marketing Approval for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan
December 22, 2025

R & D

Johnson & Johnson Obtains Approval of OPSUMIT® for the Treatment of Pediatric Patients with Pulmonary Arterial Hypertension in Japan
December 04, 2025

R & D

CAP-1002：Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase III HOPE-3 Study in Duchenne Muscular Dystrophy

Upcoming Events

February 09, 2026

IR Meeting (Q3/FY2025)
February 09, 2026

FY2025 3rd Qtr Results Announcement
November 14, 2025
IR Meeting(Q2/FY2025)
November 14, 2025
FY2025 2nd Qtr results announcement
August 07, 2025
Conference Call(Q1/FY2025)

Financial/Capital Strategy

Management Policy and Plan

Business/Financial Information

IR Library

Sustainability Management

Stock and Shareholder Information

To Our Individual Investors

IR e-mail

Subscribe (only 1 minute required) to receive the latest news by e-mail.

Most Viewed Pages

December 1-31, 2025

All Japanese Listed Companies' Website Ranking

Gomez
IR Site Ranking Silver 2025

Daiwa Investor Relations Co.Ltd. 2025 Internet IR Award

Related Link

Nippon Shinyaku’s DNA

Research & Development

Top
To Our Shareholders and Investors